EDF Ventures

BeZero Carbon operates as a global rating agency focused on the voluntary carbon market. The company offers independent, risk-based, project-level carbon ratings that are crucial for investing in carbon projects, which play a vital role in addressing climate change. By providing these ratings and associated risk tools, BeZero Carbon empowers organizations with the necessary knowledge and confidence to make informed climate decisions. The ultimate goal of the company is to enhance investment in environmental markets, contributing to a sustainable future.

DataBank Holdings, Ltd. is a data center and co-location company headquartered in Dallas, Texas, with additional facilities in the Dallas/Fort Worth area, Minneapolis/St. Paul, Eagan, Kansas City, and Atlanta. Founded in 2004, DataBank provides a comprehensive array of services, including co-location solutions that ensure security, power configurations, and cooling. The company also offers managed services such as cloud computing, virtual hosting, network connectivity, and security, along with consulting services that encompass design and implementation, migration, and continuity planning. DataBank emphasizes compliance with various industry standards, including those for payment card security and health data protection. Catering to a diverse clientele across sectors like healthcare, finance, gaming, and hospitality, DataBank is committed to optimizing IT environments and ensuring data availability for enterprises.

IntelePeer is a communications automation platform that utilizes generative AI to enhance customer interactions for businesses. By offering a cloud-based Communications Platform as a Service (CPaaS), the company provides on-demand IP communications and SIP trunking services tailored for enterprises. IntelePeer's platform integrates seamlessly with existing systems, allowing businesses to streamline their communication processes across multiple channels. Its focus on automation not only reduces operational costs but also improves customer experience by delivering efficient and effective communication solutions. The incorporation of AI and analytics further enhances the platform's capabilities, enabling clients to achieve higher levels of customer satisfaction and engagement.

Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

TransCorp Spine manufactures medical devices and procedures to restore spinal function and preserve healthy tissue. Its product includes SpinePort, a MIS access system. David Lowry, Des O'Farrell, and Scott Tuinstra founded TransCorp Spine in 2008. It has its headquarters in Byron Center in Michigan.

Sonoma Orthopedics specializes in the design and development of proprietary orthopedic implants aimed at addressing complex fractures. Utilizing the WaviBody technology platform, the company provides quick and minimally invasive surgical solutions tailored for active patients. Their focus is on fracture fixation devices that enable orthopedic surgeons to effectively repair challenging bone geometries. By offering operative treatments that facilitate faster recovery, Sonoma Orthopedics aims to help patients return to work and their daily activities sooner.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, established in 2002. It specializes in developing minimally invasive therapy solutions aimed at treating obesity and its related metabolic disorders, including type-2 diabetes and hypertension. One of its key innovations is an endoluminal bypass therapy that replicates the anatomical changes associated with the Roux-en-Y gastric bypass procedure using an adjustable, removable, and replaceable device. ValenTx's focus is on providing effective treatment options for individuals struggling with morbid obesity and related health issues.

Lycera is a preclinical-stage biopharmaceutical company dedicated to the development of small molecule immunomodulators aimed at treating autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company specializes in creating first-in-class drugs that utilize proprietary small molecules to modulate key targets involved in cellular bioenergetics and the Th17 pathway. Lycera's innovative approach seeks to provide effective oral therapies that minimize the adverse effects commonly associated with existing antiproliferative and immunosuppressive treatments. By focusing on the development of these novel agents, Lycera aims to improve patient outcomes in the management of immune disorders.

Vontoo is a provider of automated voice messaging tools that focuses on enhancing one-to-one marketing communication through the use of human voice. The company offers a web-based application that enables organizations to create, send, and track personalized voice messages tailored to the interests of individual recipients. Vontoo's platform allows clients to initiate automated calls ranging from one to millions, facilitating improved customer relationships, faster cash collection, and cost reduction. Headquartered in Indianapolis, Vontoo operates privately and is supported by various funding sources, including private investors and a venture capital firm.

Perfinity Biosciences, Inc. focuses on developing tools for protein sample preparation, offering a range of products designed to enhance reproducibility and efficiency. Its product portfolio includes immobilized enzymes, affinity reagents, optimized buffers, and software solutions. Notable offerings include Soluble Smart Digest, a stable soluble trypsin for quick and consistent digestions, and Mag Beads, tailored for proteomics applications. The QuicPrep platform combines immunoaffinity and trypsin digestion in a single process, while Flash Digest provides a rapid and stable immobilized trypsin reactor. Additionally, the Workstation automates protein separations and mass spectrometry sample preparation. Founded in 2004 and based in West Lafayette, Indiana, the company was previously known as QuadraSpec, Inc. until its name change in March 2010.

HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Eleme Medical, Inc. is a venture-backed aesthetics company focused on innovative body shaping technologies. Its flagship product, SmoothShapes® XV, enhances cellulite treatment and offers advanced protocols for pre- and post-liposuction care. This system features increased laser power and user-friendly treatment guidance, making it a valuable addition to aesthetic practices. Both SmoothShapes XV and its predecessor, launched in 2008, utilize the proprietary Photomology® platform, which combines light and laser energy with mechanical manipulation to effectively address cellulite and subcutaneous fat. These FDA-cleared devices provide long-lasting results for patients. Eleme Medical targets plastic surgeons, aesthetic dermatologists, medical spas, and other aesthetic professionals, capitalizing on the growing demand in the body shaping sector of the aesthetics market.

Alure Medical focuses on the development and commercialization of percutaneous soft tissue lift devices and delivery systems for plastic surgery utilizing patent-pending technologies.

Nanosolar, Inc. is a manufacturer of solar electricity cells and panels, focusing on cost-efficient solar energy solutions. Founded in 2001 and headquartered in San Jose, California, with additional manufacturing facilities in Berlin, Germany, the company produces products such as the Utility Panel, designed for utility-scale power plants, and SolarPly, a lightweight solar-electric cell foil that can be customized to various sizes. Nanosolar employs a proprietary printing technique for CIGS (Copper, Indium, Gallium, Selenium) solar cells, utilizing nanoparticle inks and an annealing process. This innovative approach reduces reliance on expensive high vacuum deposition equipment, allowing the company to leverage industrial printing and roll-to-roll manufacturing technologies to produce solar-electric foil efficiently and at high speeds.

IntelePeer is a communications automation platform that utilizes generative AI to enhance customer interactions for businesses. By offering a cloud-based Communications Platform as a Service (CPaaS), the company provides on-demand IP communications and SIP trunking services tailored for enterprises. IntelePeer's platform integrates seamlessly with existing systems, allowing businesses to streamline their communication processes across multiple channels. Its focus on automation not only reduces operational costs but also improves customer experience by delivering efficient and effective communication solutions. The incorporation of AI and analytics further enhances the platform's capabilities, enabling clients to achieve higher levels of customer satisfaction and engagement.

Greenplum, Inc. is a data warehousing company that specializes in developing database software designed for business intelligence and data warehousing applications. The company's flagship product, Greenplum Database, is tailored to handle multi-terabyte data warehousing requirements, making it suitable for large-scale data operations. Additionally, Greenplum Network serves as a customer and partner portal, providing instant download access to its database products. The company primarily targets clients in the telecommunications and banking sectors, addressing their specific data management and analytics needs.

Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

RockeTalk is a company that has developed a social media platform and mobile applications aimed at enhancing communication and self-expression. Founded to facilitate easier interaction among individuals, RockeTalk allows users to create and share multimedia messages, including text, voice, photos, and videos. The platform enables users to connect with friends and family, join communities, and engage in individual or group chats. Additionally, RockeTalk emphasizes safety by incorporating verification features that ensure a secure environment for its users. By offering a rich assortment of communication tools, RockeTalk aims to connect people and foster a new form of self-expression through the content they create and share.

BioSET, Inc. specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company offers a range of medical devices, including AMPLEX, an implantable combination device designed for surgical bone graft applications in spine fusion and other orthopedic procedures. BioSET's product portfolio also includes innovations for sports medicine, peptide signaling molecules, and various scaffold biomaterials, all intended for use in musculoskeletal applications such as trauma, fracture repair, and soft tissue treatments. Founded in 2001 and based in Rockville, Maryland, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

Sonoma Orthopedics specializes in the design and development of proprietary orthopedic implants aimed at addressing complex fractures. Utilizing the WaviBody technology platform, the company provides quick and minimally invasive surgical solutions tailored for active patients. Their focus is on fracture fixation devices that enable orthopedic surgeons to effectively repair challenging bone geometries. By offering operative treatments that facilitate faster recovery, Sonoma Orthopedics aims to help patients return to work and their daily activities sooner.

Sonoma Orthopedics specializes in the design and development of proprietary orthopedic implants aimed at addressing complex fractures. Utilizing the WaviBody technology platform, the company provides quick and minimally invasive surgical solutions tailored for active patients. Their focus is on fracture fixation devices that enable orthopedic surgeons to effectively repair challenging bone geometries. By offering operative treatments that facilitate faster recovery, Sonoma Orthopedics aims to help patients return to work and their daily activities sooner.

Arxan Technologies, Inc. is a leading provider of application protection solutions, specializing in safeguarding critical applications deployed across various platforms, including mobile devices, desktops, and embedded systems in the Internet of Things (IoT). The company offers a range of services designed to protect both source and binary code, enhancing the security perimeter for organizations. Its product lineup includes GuardIT, EnsureIT, TransformIT, and Arxan for Web, which utilize advanced technologies such as code hardening, obfuscation, white-box cryptography, and threat analytics. Arxan's solutions cater to diverse sectors, including financial services, healthcare, automotive, gaming, and e-commerce, and are designed to operate without interfering with software development processes or runtime performance. In addition to its software products, the company provides professional services, including risk assessments and protection design, aimed at ensuring comprehensive security for its clients. Founded in 2001 and headquartered in San Francisco, California, Arxan Technologies has established strategic alliances with notable firms to enhance its offerings.

Greenplum, Inc. is a data warehousing company that specializes in developing database software designed for business intelligence and data warehousing applications. The company's flagship product, Greenplum Database, is tailored to handle multi-terabyte data warehousing requirements, making it suitable for large-scale data operations. Additionally, Greenplum Network serves as a customer and partner portal, providing instant download access to its database products. The company primarily targets clients in the telecommunications and banking sectors, addressing their specific data management and analytics needs.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Lycera is a preclinical-stage biopharmaceutical company dedicated to the development of small molecule immunomodulators aimed at treating autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. The company specializes in creating first-in-class drugs that utilize proprietary small molecules to modulate key targets involved in cellular bioenergetics and the Th17 pathway. Lycera's innovative approach seeks to provide effective oral therapies that minimize the adverse effects commonly associated with existing antiproliferative and immunosuppressive treatments. By focusing on the development of these novel agents, Lycera aims to improve patient outcomes in the management of immune disorders.

ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, established in 2002. It specializes in developing minimally invasive therapy solutions aimed at treating obesity and its related metabolic disorders, including type-2 diabetes and hypertension. One of its key innovations is an endoluminal bypass therapy that replicates the anatomical changes associated with the Roux-en-Y gastric bypass procedure using an adjustable, removable, and replaceable device. ValenTx's focus is on providing effective treatment options for individuals struggling with morbid obesity and related health issues.

Greenplum, Inc. is a data warehousing company that specializes in developing database software designed for business intelligence and data warehousing applications. The company's flagship product, Greenplum Database, is tailored to handle multi-terabyte data warehousing requirements, making it suitable for large-scale data operations. Additionally, Greenplum Network serves as a customer and partner portal, providing instant download access to its database products. The company primarily targets clients in the telecommunications and banking sectors, addressing their specific data management and analytics needs.

Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

BioSET, Inc. specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company offers a range of medical devices, including AMPLEX, an implantable combination device designed for surgical bone graft applications in spine fusion and other orthopedic procedures. BioSET's product portfolio also includes innovations for sports medicine, peptide signaling molecules, and various scaffold biomaterials, all intended for use in musculoskeletal applications such as trauma, fracture repair, and soft tissue treatments. Founded in 2001 and based in Rockville, Maryland, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.

Oxand is an international consulting and solutions provider specializing in capital-intensive assets across various sectors, including energy, transportation, and public/private properties. The company offers tailored consultancy, training, and IT solutions that emphasize risk-informed decision support to enhance asset performance and return on investment. With expertise in optimizing life cycle decisions, Oxand helps clients reduce costs by 10 to 30%, extend asset life, and minimize delays in large projects. The firm has analyzed assets valued at over 1,150 billion Euros, demonstrating its extensive experience and commitment to improving client outcomes. Supported by proprietary technologies and comprehensive data libraries, Oxand ensures that its solutions comply with industry standards, providing clients with the tools necessary for effective risk management and decision-making.

HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Xtera Communications, Inc. was a provider of optical transport solutions, specializing in Raman amplification-enabled systems for terrestrial and submarine networks. Founded in 1998 and headquartered in Allen, Texas, the company catered to telecommunications service providers, content service providers, enterprises, and government entities globally. Xtera offered a range of products and services, including un-repeatered and repeatered optical systems, designed to enhance network reach and capacity. Its solutions were tailored to meet individual customer needs, encompassing full turnkey systems, open architecture designs, and specific product supply. Despite its previous success in expanding its customer base and product portfolio, Xtera faced financial difficulties that led to its Chapter 11 bankruptcy filing in November 2016, which was later converted to Chapter 7 liquidation in February 2017.

Arxan Technologies, Inc. is a leading provider of application protection solutions, specializing in safeguarding critical applications deployed across various platforms, including mobile devices, desktops, and embedded systems in the Internet of Things (IoT). The company offers a range of services designed to protect both source and binary code, enhancing the security perimeter for organizations. Its product lineup includes GuardIT, EnsureIT, TransformIT, and Arxan for Web, which utilize advanced technologies such as code hardening, obfuscation, white-box cryptography, and threat analytics. Arxan's solutions cater to diverse sectors, including financial services, healthcare, automotive, gaming, and e-commerce, and are designed to operate without interfering with software development processes or runtime performance. In addition to its software products, the company provides professional services, including risk assessments and protection design, aimed at ensuring comprehensive security for its clients. Founded in 2001 and headquartered in San Francisco, California, Arxan Technologies has established strategic alliances with notable firms to enhance its offerings.

Arbor Networks specializes in securing complex networks against DDoS attacks and advanced threats. The company offers a suite of products that provides customers with detailed insights into their own networks while also leveraging its ATLAS threat intelligence infrastructure for a broader understanding of global Internet traffic and emerging threats. With contributions from over 330 service providers generating 120 Tbps of traffic intelligence, Arbor's Security Engineering & Response Team develops protective measures that are integrated into customer products to combat DDoS and malware threats. Arbor's DDoS Solutions are adaptable, catering to various deployment needs, including virtual solutions, network-embedded systems, and enterprise appliances. The Arbor Cloud service combines on-premises and cloud-based mitigation for comprehensive DDoS defense. Additionally, Arbor Advanced Threat Solutions utilize integrated Netflow and Packet Capture technology to enhance network-wide situational awareness and provide deep traffic visibility, enabling effective threat detection and response through real-time insights and historical analysis. The company's focus is on ensuring the availability of critical infrastructure while safeguarding against advanced threats.

HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Virtual Silicon Technology is a provider of SIP solutions to manufacturers and designers of system-on-chip semiconductors.

Xtera Communications, Inc. was a provider of optical transport solutions, specializing in Raman amplification-enabled systems for terrestrial and submarine networks. Founded in 1998 and headquartered in Allen, Texas, the company catered to telecommunications service providers, content service providers, enterprises, and government entities globally. Xtera offered a range of products and services, including un-repeatered and repeatered optical systems, designed to enhance network reach and capacity. Its solutions were tailored to meet individual customer needs, encompassing full turnkey systems, open architecture designs, and specific product supply. Despite its previous success in expanding its customer base and product portfolio, Xtera faced financial difficulties that led to its Chapter 11 bankruptcy filing in November 2016, which was later converted to Chapter 7 liquidation in February 2017.

MetaMatrix is an U.S.-based technology company that created the first true Enterprise Information Integration (EII) software product.

IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Ican Inc., is a provider of Internet-based information and tools for health professionals.

Ican provides Internet-based information and tools for health professionals.

Alfalight specializes in the design and manufacture of high-power diode lasers tailored for industrial, defense, and telecommunications applications. The company utilizes advanced aluminum-free active region (ALFA) laser structures, which contribute to the production of laser diodes that are noted for their high reliability and efficiency. Alfalight's product range includes short-wave infrared, near-infrared, and visible lasers, alongside various laser and electro-optical systems. These innovations position Alfalight as a key player in meeting the demands of both security and telecommunication sectors.

Centromine offers a browser-based, internet-accessed, enterprise-wide software applications and services for the health care market. Its applications allow behavioral health care programs and providers to manage the delivery and associated quality and cost of services completely over the internet.

IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Pixelworks, Inc. is a semiconductor and software company that specializes in video and pixel processing solutions for high-end display applications. Founded in 1997 and headquartered in San Jose, California, Pixelworks designs and markets a range of products including image processor integrated circuits (ICs), video co-processor ICs, and transcoder ICs. These products are utilized in various devices such as smartphones, tablets, projectors, and digital signage, facilitating high-quality video experiences across multiple formats and sources. The company leverages its proprietary technologies to help manufacturers enhance their display products while also enabling rapid development and customization to reduce time to market. Pixelworks maintains an extensive intellectual property portfolio, holding numerous patents related to the visual display of digital images, underscoring its commitment to innovation in the visual processing sector. The company sells its solutions through a direct sales force, as well as distributors and manufacturers’ representatives globally.

IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.